Elderly patients undergoing transcatheter aortic valve replacement (TAVR) for symptomatic severe aortic stenosis may fare better with the SAPIEN 3 prosthesis than with the ACURATE neo transcatheter heart valve, according to a recent study presented at the 31st Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2019).
Transitioning from dual antiplatelet therapy (DAPT) to aspirin monotherapy at 3 months following implantation of a thin-strut bioresorbable-polymer stent is safe for patients with high bleeding risk (HBR), according to the results of the EVOLVE Short DAPT trial presented at the 31st Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
Standard-dose ticagrelor significantly increased the risk of bleeding events among Korean patients with acute coronary syndrome (ACS) compared with clopidogrel, according to the TICAKOREA* study presented at TCT 2019.
There appears to be little benefit to adding aspirin to ticagrelor in patients with acute coronary syndromes (ACS) who have undergone percutaneous coronary intervention (PCI), with a similar rate of all-cause mortality and new Q-wave myocardial infarction (MI) at 1 year between those who received ticagrelor monotherapy and a ticagrelor-aspirin combo, according to a non-prespecified, post hoc exploratory analysis of the GLOBAL LEADERS* trial.
Treatment with apixaban and a P2Y12 inhibitor, but leaving off aspirin, may be an effective and safe option for patients with atrial fibrillation (AF) and acute coronary syndrome (ACS) regardless of presentation, a new analysis of the AUGUSTUS* trial has shown. However, questions remain on when to drop aspirin in patients with AF, requiring both dual antiplatelet therapy (DAPT) and anticoagulation.
Individuals with left main coronary artery disease (CAD) who underwent percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) continued to show similar rates of the primary outcome (composite of death, stroke, or myocardial infarction), highlighting the potential of PCI as a CABG alternative in this patient setting, according to the final results of the EXCEL* trial presented at TCT 2019.
Ticagrelor monotherapy significantly reduces bleeding without increasing the risk of ischaemic events (all-cause death and myocardial infarction (MI)) in high-risk patients who have undergone percutaneous coronary intervention (PCI), according to the TWILIGHT* study presented at TCT 2019.
Several strategies have been proposed to help manage the adverse events (AEs) that emerged during the BEACON CRC trial which assessed the effect of encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) who had progressed after one or two prior regimens.
Switching to a dual therapy of dolutegravir/lamivudine (DTG/3TC) was noninferior to continuing on a TAF*-based regimen in maintaining virologic suppression over 96 weeks in virally suppressed adults with HIV-1, according to the long-term data from TANGO presented at the 2020 HIV Glasgow Congress.